Chemotherapy Induced Neutropenia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Bio

Posted on
by

Chemotherapy Induced Neutropenia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Bio
DelveInsight’s “Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia.

DelveInsight’s “Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia Market Forecast

 

Some of the key facts of the Chemotherapy Induced Neutropenia Market Report: 

  • The Chemotherapy Induced Neutropenia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In the 7MM, 1,816,200 cancer patients were expected to be receiving chemotherapy overall in 2021
  • The US had 705,300 cases of cancer patients receiving chemotherapy in 2021, which was the most of any other country. With 322,300 cancer patients receiving chemotherapy in Japan, it came in second out of 7MM countries in 2021
  • The UK has 167,000 cancer patients receiving chemotherapy in 2021. Additionally, during the projection period, a rise in these cases is anticipated.
  • Key Chemotherapy Induced Neutropenia Companies: Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring Pharmaceuticals, Dong-A ST Co., Ltd., Tianjin SinoBiotech Ltd., Sandoz, Myelo Therapeutics GmbH, AviGenics, Spectrum Pharmaceuticals, Inc, Sandoz, Eurofarma Laboratorios S.A., Sanofi, and others
  • Key Chemotherapy Induced Neutropenia Therapies: EC-18, ALRN-6924, F-627 (Ryzneuta), Myelo001, Plinabulin, Pegfilgrastim, PEG-G-CSF, HSA-GCSF, LA-EP2006, Myelo001, AVI-014 versus Filgrastim, SPI-2012, LA-EP2006, Filgrastim (Eurofarma), LENOGRASTIM (GRANOGYTE 34), and others
  • The Chemotherapy Induced Neutropenia epidemiology based on gender analyzed that out of the total patients on chemotherapy, maximum patients are at intermediate-high risk for Chemotherapy Induced Neutropenia
  • The Chemotherapy Induced Neutropenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy Induced Neutropenia pipeline products will significantly revolutionize the Chemotherapy Induced Neutropenia market dynamics.

 

Chemotherapy Induced Neutropenia Overview

The earliest cellular elements of the inflammatory response and essential elements of innate immunity, neutrophils are a component of the phagocyte system. The average absolute neutrophil count (ANC) in healthy individuals ranges from 1,500 to 7000/mm of blood. Neutropenia is the condition that occurs when neutrophil counts fall below 1,500/mm of blood.

 

Get a Free sample for the Chemotherapy Induced Neutropenia Market Report 

https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market

 

Chemotherapy Induced Neutropenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chemotherapy Induced Neutropenia Epidemiology Segmentation:

The Chemotherapy Induced Neutropenia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chemotherapy Induced Neutropenia
  • Prevalent Cases of Chemotherapy Induced Neutropenia by severity
  • Gender-specific Prevalence of Chemotherapy Induced Neutropenia
  • Diagnosed Cases of Episodic and Chronic Chemotherapy Induced Neutropenia

 

Download the report to understand which factors are driving Chemotherapy Induced Neutropenia epidemiology trends @ Chemotherapy Induced Neutropenia Epidemiology Forecast

 

Chemotherapy Induced Neutropenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Neutropenia market or expected to get launched during the study period. The analysis covers Chemotherapy Induced Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chemotherapy Induced Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Chemotherapy Induced Neutropenia Therapies and Key Companies

  • EC-18: Enzychem Lifesciences Corporation
  • ALRN-6924: Aileron Therapeutics
  • F-627 (Ryzneuta): Evive Biotech
  • Myelo001: Myelo therapeutics
  • Plinabulin: BeyondSpring Pharmaceuticals
  • Pegfilgrastim: BeyondSpring Pharmaceuticals Inc.
  • PEG-G-CSF: Dong-A ST Co., Ltd.
  • HSA-GCSF: Tianjin SinoBiotech Ltd.
  • LA-EP2006: Sandoz
  • Myelo001: Myelo Therapeutics GmbH
  • AVI-014 versus Filgrastim: AviGenics
  • SPI-2012: Spectrum Pharmaceuticals, Inc
  • LA-EP2006: Sandoz
  • Filgrastim (Eurofarma): Eurofarma Laboratorios S.A.
  • LENOGRASTIM (GRANOGYTE 34): Sanofi

 

Discover more about therapies set to grab major Chemotherapy Induced Neutropenia market share @ Chemotherapy Induced Neutropenia Treatment Market

 

Chemotherapy Induced Neutropenia Market Strengths

  • The growth in the cancer patient population, along with a rise in the comorbidities and use of certain drugs (chemotherapies) over the globe, is contributing to the rise in the incidence of CIN
  • An increase in clinical trials activity for emerging therapies will boost the market
  • Rising awareness about the disease among clinicians and patients

 

Chemotherapy Induced Neutropenia Market Opportunities

  • Limited development in the mechanism of action of approved therapies in the market offers a great opportunity for the investment and development of emerging novel therapies
  • Medications with better safety for long term use and low treatment duration are the current unmet need of the CIN market
  • Low-cost therapies and therapies with good patient compliance might be the game-changer for the CIN treatment market

 

Scope of the Chemotherapy Induced Neutropenia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Chemotherapy Induced Neutropenia Companies: Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring Pharmaceuticals, Dong-A ST Co., Ltd., Tianjin SinoBiotech Ltd., Sandoz, Myelo Therapeutics GmbH, AviGenics, Spectrum Pharmaceuticals, Inc, Sandoz, Eurofarma Laboratorios S.A., Sanofi, and others
  • Key Chemotherapy Induced Neutropenia Therapies: EC-18, ALRN-6924, F-627 (Ryzneuta), Myelo001, Plinabulin, Pegfilgrastim, PEG-G-CSF, HSA-GCSF, LA-EP2006, Myelo001, AVI-014 versus Filgrastim, SPI-2012, LA-EP2006, Filgrastim (Eurofarma), LENOGRASTIM (GRANOGYTE 34), and others
  • Chemotherapy Induced Neutropenia Therapeutic Assessment: Chemotherapy Induced Neutropenia current marketed and Chemotherapy Induced Neutropenia emerging therapies
  • Chemotherapy Induced Neutropenia Market Dynamics: Chemotherapy Induced Neutropenia market drivers and Chemotherapy Induced Neutropenia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Chemotherapy Induced Neutropenia Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy Induced Neutropenia Market Access and Reimbursement 

 

To know more about Chemotherapy Induced Neutropenia companies working in the treatment market, visit @ Chemotherapy Induced Neutropenia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Chemotherapy Induced Neutropenia Market Report Introduction

2. Executive Summary for Chemotherapy Induced Neutropenia

3. SWOT analysis of Chemotherapy Induced Neutropenia

4. Chemotherapy Induced Neutropenia Patient Share (%) Overview at a Glance

5. Chemotherapy Induced Neutropenia Market Overview at a Glance

6. Chemotherapy Induced Neutropenia Disease Background and Overview

7. Chemotherapy Induced Neutropenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Chemotherapy Induced Neutropenia 

9. Chemotherapy Induced Neutropenia Current Treatment and Medical Practices

10. Chemotherapy Induced Neutropenia Unmet Needs

11. Chemotherapy Induced Neutropenia Emerging Therapies

12. Chemotherapy Induced Neutropenia Market Outlook

13. Country-Wise Chemotherapy Induced Neutropenia Market Analysis (2019–2032)

14. Chemotherapy Induced Neutropenia Market Access and Reimbursement of Therapies

15. Chemotherapy Induced Neutropenia Market Drivers

16. Chemotherapy Induced Neutropenia Market Barriers

17.  Chemotherapy Induced Neutropenia Appendix

18. Chemotherapy Induced Neutropenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services